Meet David Hoffmann, member of the Board of Directors & Corporate Secretary of Swizzard Pharma AG
Updated: 14 hours ago
Swizzard Pharma AG, a solution provider to maximize the value of medical breakthroughs in Switzerland,is proud to introduce David Hoffmann, Swizzard’s Corpororate Secretary and an established Member of the Board of Directors.
David has an extensive education, including an MBA in Pharmaceutical & General Management and an LLM in International Business Law, to complement his strong scientific background in health and neuroscience.
After several years in strategy consulting, David joined Celgene, a biopharmaceutical company and leader in the space of oncology and hematology, in 2016. As Compliance Officer, he held a range of responsibilities and was also in charge of managing key commercial products including the launch of the highly scientific CAR-T cell therapies at Bristol Myers Squibb. Recently, David joined Blueprint Medicines, leading the international commercial operations of this US Biotech which is in the process of entering the European market.
“It is exciting to bring my expertise to the board of Swizzard Pharma AG and engage in great strategic discussions around how to help innovative biotech companies bring value to the Swiss healthcare market,” says David Hoffmann. David contributes a diverse educational background and a strong track record in the biopharmaceutical industry to the Board of Directors at Swizzard Pharma AG. With his skillset, he complements the board and its work on strategic decision making, risk management and the establishment of a strong legal and compliance backbone.
“With his broad educational background and relevant experience in the biotech industry, David is a highly knowledgeable resource for Swizzard and our clients,” says Michael Zürcher, CEO of Swizzard. “We’re excited to have him on board.”